title: A comparison of the inhibitory effects of immunosuppressive agents cyclosporine, tetranactin, and didemnin B on human T cell responses in vitro.
abstract: The agents cyclosporine, tetranactin (TN), and didemnin B (DB) were compared for their ability to inhibit proliferative human T cell responses in vitro, using anti-CD3, PHA, alloantigen, or tetanus toxoid as stimuli and using monocytes or Langerhans cells as antigen-presenting cells/accessory cells (APC/AC). We found that all three agents suppressed T cell activation in a dose-dependent fashion, irrespective of the stimulus of APC/AC type used. Both T cells and APC/AC were affected by the drugs. DB appeared to be the most potent suppressive drug (IC50 = 1-4 ng/ml), whereas CsA and TN exerted approximately similar potency (IC50 = 50-60 ng/ml). Remarkably however, DB was toxic at a concentration of 10 ng/ml, which is quite close to the inhibition-inducing dose. No toxicity was observed with CsA and TN at doses up to 5000 ng/ml. The agents TN and DB could interrupt ongoing T cell responses and could block responsiveness to exogenous recombinant IL-2. Expression of IL-2 receptors was slightly inhibited by all three drugs. Expression of MHC class II molecule HLA-D and of adhesion molecules LFA-1, LFA-3, and ICAM-1 was clearly reduced by DB, giving an explanation for the observed inhibition of cluster formation between T cells and APC/AC. Except for a slight reduction of LFA-3 by TN, CsA and TN did not affect the expression of any of these cell surface markers or the formation of clusters. Differences in the effects of CsA, TN, and DB on immune responses in vitro and on the phenotype of T cells and APC/AC suggest that these immunosuppressive drugs have different inhibitory mechanisms.
authors.affiliation: Department of Dermatology, Academisch Medisch Centrum, University of Amsterdam, The Netherlands.
authors.forename: M B
authors.initials: MB
authors.lastname: Teunissen
authors.forename: F H
authors.initials: FH
authors.lastname: Pistoor
authors.forename: H A
authors.initials: HA
authors.lastname: Rongen
authors.forename: M L
authors.initials: ML
authors.lastname: Kapsenberg
authors.forename: J D
authors.initials: JD
authors.lastname: Bos
mesh_terms: D002470:Cell Survival / Q000187:drug effects; D016572:Cyclosporine / Q000494:pharmacology*; D047630:Depsipeptides; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011714:Pyrans / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects*
chemical_list: D047630:Depsipeptides; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D010456:Peptides, Cyclic; D011714:Pyrans; C003417:tetranactin; C030051:didemnins; D016572:Cyclosporine